GHRL
Appetite-regulating hormone
Also known as: ghrelin, GHRL_HUMAN, MTLRP, obestatin
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UBU3
- Gene
- GHRL
- Ensembl
- ENSG00000157017
- Chromosome
- 3
- Canonical length
- 117 aa
- Protein class
- Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes the ghrelin-obestatin preproprotein that is cleaved to yield two peptides, ghrelin and obestatin. Ghrelin is a powerful appetite stimulant and plays an important role in energy homeostasis. Its secretion is initiated when the stomach is empty, whereupon it binds to the growth hormone secretagogue receptor in the hypothalamus which results in the secretion of growth hormone (somatotropin). Ghrelin is thought to regulate multiple activities, including hunger, reward perception via the mesolimbic pathway, gastric acid secretion, gastrointestinal motility, and pancreatic glucose-stimulated insulin secretion. It was initially proposed that obestatin plays an opposing role to ghrelin by promoting satiety and thus decreasing food intake, but this action is still debated. Recent reports suggest multiple metabolic roles for obestatin, including regulating adipocyte function and glucose metabolism. Alternative splicing results in multiple transcript variants. In addition, antisense transcripts for this gene have been identified and may potentially regulate ghrelin-obestatin preproprotein expression. [provided by RefSeq, Nov 2014]
Canonical amino-acid sequenceUniProt
117 residues, UniProt reviewed canonical sequence.
>Q9UBU3|GHRL
1 MPSPGTVCSL LLLGMLWLDL AMAGSSFLSP EHQRVQQRKE SKKPPAKLQP RALAGWLRPE
61 DGGQAEGAED ELEVRFNAPF DVGIKLSGVQ YQQHSQALGK FLQDILWEEA KEAPADKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GHRL can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.58
- Highest tissue expression
- 356 nTPM
Expression across tissuesHPA
Tissue
- stomach: 356 nTPM
- duodenum: 18 nTPM
- lymph node: 6.9 nTPM
- epididymis: 4.5 nTPM
- bone marrow: 4.2 nTPM
- pancreas: 3.9 nTPM
Single-cell type
- neuroendocrine cells: 12,020 nCPM
- gastric chief cells: 891 nCPM
- pancreatic islet cells: 838 nCPM
- mucous neck cells: 34 nCPM
- epididymal principal cells: 28 nCPM
- cdc: 27 nCPM
Immune cell
- myeloid DC: 42 nTPM
- plasmacytoid DC: 29 nTPM
- neutrophil: 26 nTPM
- basophil: 18 nTPM
- eosinophil: 12 nTPM
- classical monocyte: 11 nTPM
Brain region
- cerebellum: 10 nTPM
- basal ganglia: 9.9 nTPM
- cerebral cortex: 9.4 nTPM
- pons: 8.8 nTPM
- amygdala: 8.6 nTPM
- choroid plexus: 7.9 nTPM
ReferencesPubMed · IEDB
Publications for GHRL from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
4 publications
- Autoantibodies against appetite-regulating peptide hormones and neuropeptides: putative modulation by gut microflora.
2008 · Nutrition · RCR 3.5 · 131 citations - Ghrelin reactive autoantibodies in restrictive anorexia nervosa.
2011 · Nutrition · RCR 1.8 · 51 citations - IgG Anti-ghrelin Immune Complexes Are Increased in Rheumatoid Arthritis Patients Under Biologic Therapy and Are Related to Clinical and Metabolic Markers.
2019 · Front Endocrinol (Lausanne) · RCR 0.7 · 13 citations - Detection of natural autoimmunity to ghrelin in diabetes mellitus.
2024 · Front Med Technol · RCR 0.2 · 1 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.97
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.8
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- actin polymerization or depolymerization
- adult feeding behavior
- cartilage development
- decidualization
- dendrite development
- excitatory postsynaptic potential
- G protein-coupled receptor signaling pathway
- gastric acid secretion
- glucose metabolic process
- growth hormone secretion
- hormone-mediated signaling pathway
- negative regulation of angiogenesis
- negative regulation of apoptotic process
- negative regulation of circadian sleep/wake cycle, REM sleep
- negative regulation of endothelial cell proliferation
- negative regulation of inflammatory response
- negative regulation of insulin secretion
- negative regulation of interleukin-1 beta production
- negative regulation of interleukin-6 production
- negative regulation of locomotion
- negative regulation of tumor necrosis factor production
- positive regulation of adipose tissue development
- positive regulation of appetite
- positive regulation of bone development
- positive regulation of circadian sleep/wake cycle, non-REM sleep
- positive regulation of cold-induced thermogenesis
- positive regulation of corticotropin secretion
- positive regulation of cortisol secretion
- positive regulation of cytosolic calcium ion concentration
- positive regulation of eating behavior
- positive regulation of growth hormone receptor signaling pathway
- positive regulation of growth hormone secretion
- positive regulation of growth rate
- positive regulation of insulin secretion
- positive regulation of insulin secretion involved in cellular response to glucose stimulus
- positive regulation of MAPK cascade
- positive regulation of multicellular organism growth
- positive regulation of small intestinal transit
- positive regulation of small intestine smooth muscle contraction
- positive regulation of sprouting angiogenesis
- positive regulation of synapse assembly
- positive regulation of vascular endothelial cell proliferation
- postsynaptic modulation of chemical synaptic transmission
- regulation of cell population proliferation
- regulation of gastric motility
- regulation of postsynapse organization
- regulation of response to food
- regulation of transmission of nerve impulse
- response to electrical stimulus
- response to estrogen
- response to hormone
- synapse assembly
- cortisol secretion
- positive regulation of gastric mucosal blood circulation
Molecular functions
- G protein-coupled receptor binding
- growth hormone-releasing hormone activity
- protein tyrosine kinase activator activity
- ghrelin receptor binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GHRL as an antibody target. Whether an autoantibody or antibody against GHRL could matter depends on whether native GHRL is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GHRL is annotated as secreted, so native GHRL circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label GHRL as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...